diff --git a/src/data/hptimelinedata.tsx b/src/data/hptimelinedata.tsx
index 66555c953219488c6a8fb341d86707d9a02d24bc..ab43a725001dbc026fc139eecb67f1b79a2ff818 100644
--- a/src/data/hptimelinedata.tsx
+++ b/src/data/hptimelinedata.tsx
@@ -447,6 +447,9 @@ export const timelinedata: Array<TimelineDatenpunkt>  = [
     insights: [<div className="row">
       <div className="col"><img src="https://static.igem.wiki/teams/5247/photos/hp/olario-abbildung1.svg"></img>
       <br/>
+      <br/>
+      <br/>
+      <br/>
       <img src="https://static.igem.wiki/teams/5247/photos/hp/proandcon-png.svg"></img>
       </div>
       <div className="col"><p>We invited Max, our CF patient contact, to join Dr. Olariu in discussing the intersection of academic research, clinical application, and patient needs. Through our connection with <a href="https://www.cfvww.org" >CF Vests Worldwide</a>, an organization dedicated to providing life-saving therapy vests to  Cystic Fibrosis patients globally, we gained insights into the challenges faced by CF patients, particularly in regions like Thailand, where access to advanced treatments and medical devices is limited. The conversation highlighted the critical role of early diagnosis and intervention, as well as the quality-of-life challenges many patients endure due to conventional treatments that may not be effective for everyone. Innovative approaches, such as our SORT LNP (lipid nanoparticle) delivery system, present promising alternatives for CF therapy. This system, which allows for RNA encapsulation and administration via dry spray inhalation, could revolutionize treatment by targeting lung cells more effectively, particularly in resource-limited settings. Dr. Olariu underscored the need for psychological support and coordinated care for CF patients, emphasizing that novel therapies like LNP-based gene treatments have the potential to improve treatment efficacy and accessibility, ultimately reducing the lifelong burden of care for patients and their families. </p>